EU Says Nitrosamine Risk Info Also Needed For New Drug Filings
Incomplete Info May Impact Granting Of Marketing Authorization
Companies seeking approval of new drugs must provide information on nitrosamine-related risk evaluation either as part of their marketing application or during the evaluation process.
